PDL Can’t Find Buyer, Plans More Cutbacks
This article was originally published in The Pink Sheet Daily
Executive Summary
Fourth-quarter numbers disappoint, but savings could brighten picture.
You may also be interested in...
PDL Stockholders Get $500 Million, As Promised
Troubled biotech spins off R&D, leaves shell to manage royalty income.
PDL Stockholders Get $500 Million, As Promised
Troubled biotech spins off R&D, leaves shell to manage royalty income.
PDL Divests Another Business – Genmab Gets Antibody Facility For $240 Million
Danish firm adds capacity to produce clinical and commercial scale material for its pipeline.